Welcome to our dedicated page for CareDx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CareDx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CareDx's regulatory disclosures and financial reporting.
CareDx, Inc. reported that Secretary and General Counsel Jeffrey Adam Novack had 1,292 shares of common stock withheld by the company at $21.95 per share to cover tax obligations tied to the vesting of restricted stock units. After this tax-withholding disposition, he directly holds 112,632 shares of CareDx common stock.
CareDx, Inc. President and CEO John Walter Hanna Jr. sold 4,835 shares of Common Stock in an open-market transaction at a weighted average price between $24.00 and $24.02 per share on June 4, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 13, 2024. Following the sale, he continues to hold 671,640 shares directly, indicating the transaction represents only a small portion of his overall position.
Form 144 filing reports proposed sales of Common Stock related to option exercises and vested RSUs. The filing lists 706 shares tied to an exercise of stock options dated 06/04/2026 and 4,129 shares tied to Restricted Stock Units dated 04/15/2025. The filing also records 10,282 shares sold on 04/16/2026 under a 10b5-1 plan for net proceeds of $217,155.84.
CareDx, Inc. director Arthur A. Torres reported selling a total of 10,570 shares of common stock in open-market transactions over two days. He sold 4,086 shares on May 14, 2026 at a weighted average price of $20.9735 per share, in trades ranging from $20.96 to $21.03. He then sold 6,484 shares on May 15, 2026 at a weighted average price of $19.8917 per share, in trades ranging from $19.73 to $20.105. After these sales, Torres directly holds 38,665 shares of CareDx common stock.
CDNA insider filing: Arthur Torres reported a Rule 144 notice related to restricted Common stock and recent sales. The filing lists 6,484 restricted Common shares noted under "Securities To Be Sold" with an effective date of 06/14/2025. It also reports 4,086 Common shares sold on 05/14/2026 for $85,697.72.
CareDx, Inc. reported that its Secretary and General Counsel, Jeffrey Adam Novack, executed an open-market sale of 2,688 shares of common stock on May 5, 2026 at a weighted average price of 20.6775 per share. After the sale, he directly owned 113,924 shares of CareDx common stock. The transaction was effected under a pre-arranged Rule 10b5-1 trading plan, which had been adopted on September 4, 2025, and the sale prices ranged from 20.405 to 21.26 per share.
CareDx, Inc. reported a routine insider tax-related transaction by its Secretary and General Counsel, Jeffrey Adam Novack. On May 1, 2026, 2,873 shares of common stock were withheld by the company at $21.50 per share to cover tax obligations arising from the vesting of restricted stock units. After this withholding, Novack directly held 116,612 shares of CareDx common stock. This was a compensation-related tax-withholding event, not an open-market purchase or sale.
CareDx, Inc. filed an automatic shelf registration on Form S-3 to register an unspecified aggregate amount of common stock, preferred stock, debt securities, warrants, subscription rights and/or units from time to time after this registration statement becomes effective. The shelf prospectus describes broad terms and distribution methods and states that each offering will be detailed in a prospectus supplement.
The prospectus notes 51,274,651 shares of common stock outstanding as of March 31, 2026, authorized capital of 100,000,000 common shares and 10,000,000 preferred shares, and discloses outstanding equity awards and the Nasdaq listing (symbol CDNA).